Why Oncolytics Biotech Inc.’s (ONCY) Stock Is Down 8.51%
As of Friday, October 16, Oncolytics Biotech Inc.’s ONCY share price has dipped by 8.51%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (“GI”) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Commentary & Analysis
Why Oncolytics Biotech Inc.’s (ONCY) Stock Is Down 6.92%
As of Wednesday, October 14, Oncolytics Biotech Inc.’s ONCY share price has dipped by 6.92%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Oncolytics Biotech Inc.’s (ONCY) Stock Is Up 12.65%
As of Wednesday, October 14, Oncolytics Biotech Inc.’s ONCY share price has surged by 12.65%, which has investors questioning if this is right time to sell.Omar Beirat
Why Oncolytics Biotech Inc.’s (ONCY) Stock Is Down 7.54%
As of Monday, October 12, Oncolytics Biotech Inc.’s ONCY share price has dipped by 7.54%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Oncolytics Biotech Inc.’s (ONCY) Stock Is Down 6.09%
As of Thursday, October 08, Oncolytics Biotech Inc.’s ONCY share price has dipped by 6.09%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | ONCY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $65.2 | $229.3 | 18% |
|
| Shares Out (Mil) | 119.7 | 53.4 | 66% |
|
| Institutional Ownership | 68.4% | 92.9% | 42% |
|
| Float (Mil) | 125.5 | 41.4 | 65% |
|
| Beta | 1.15 | 0.94 | 68% |
|
| Avg Daily Volume (000s) | 1,785 | 533 | 80% |
|
| Price Change (52-week) |
(54.9%) | 47.5% | 18% |
|
| Growth | ONCY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (10.2%) | (10.1%) | 29% |
|
| EPS (5yr) | 7.3% | 15.8% | 43 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (16.5%) | (15.7%) | 44% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | 2 | 5 | |
| Current EPS | na | ($0.270) | ($0.241) | |
| Month Ago EPS | na | ($0.267) | ($0.199) | |
| # Rev Up | na | 0 | 0 | |
| # Rev Down | na | 1 | 1 | |
| Three Months Ago EPS | na | ($0.228) | ($0.199) | |
| Year/Year Chg | na | (10.0%) | (37.0%) | |
| Financials | ONCY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($38) | ($44) | 19% |
|
| EPS (TTM) | ($0.341) | ($1.600) | 30% |
|
| Operating Cash Flow (TTM) (Mil) | ($27) | ($34) | 13% |
|
| Net Cash Flow (TTM) (Mil) | ($6) | $3 | 33% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 13% |
|
| Enterprise Value (Q1) (Mil) | $96 | $179 | 21% |
|
| Valuation | ONCY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.17 | na |
|
| P/E | na | 20.3 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | ONCY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (335.7%) | (47.1%) | 1% |
|
| ROE | na | (53.5%) | na |
|
| Liabilities to Assets | 180.4% | 29.3% | 99% |
|
| F-Score | 1 | 2 | 1% |
|
Oncolytics Biotech Inc. did not pass any screens on 10/21/2026.
